Prolytic
Prolytic is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
Double-blind placebo-controlled clinical trial (Phase 1b/2a) to evaluate safety and efficacy of IM-250 administration in patients with recurrent genital herpes.
Sponsor Innovative Molecules GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
IB1001-304: Effects of N-Acetyl-L-Leucine on CACNA1A Disorders: A Phase III, randomized, placebo-controlled, double-blind, crossover study
Sponsor Intrabio Limited
- Start (EU)
- Latest update
- Estimated end
A Phase I/IIa, open-label, dose finding, safety, tolerability and exploratory trial of THEO-260 in patients with high grade serous or endometrioid ovarian cancer
Sponsor Theolytics Limited
- Start (EU)
- Latest update
- Estimated end
Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Phase III, randomized, placebo-controlled, double-blind, crossover study
Sponsor Intrabio Limited
- Start (EU)
- Latest update
- Estimated end
A Phase III study to evaluate the efficacy of INM004 (Shiga antitoxin) in pediatric patients with Hemolytic Uremic Syndrome associated to infection by Shiga toxin-producing Escherichia coli
Sponsor Chemo Research S.L.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Prolytic?
The 2026-10-09 snapshot links Prolytic to 5 distinct CTIS trials. Recorded services include Laboratory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Prolytic?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Gynecology, Infectious Disease, Neurology. Recorded phases include Phase 1, Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Prolytic conducted?
The linked trials record locations in 13 countries, including Germany, Spain, Italy, Austria, Belgium. These are trial locations, not confirmed office locations or countries where Prolytic delivered services.
What can this page tell me about Prolytic's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Prolytic. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Prolytic GmbH